O. Komina

发表

Signaling of DNA damage is not sufficient to induce p53 response: (Re)Activation of wt p53 protein strongly depends on cellular context

J. Węsierska‐Gądek, G. Schmid, M. Kramer, 2008, Journal of cellular biochemistry.

Reconstitution of human MCF‐7 breast cancer cells with caspase‐3 does not sensitize them to action of CDK inhibitors

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2011, Journal of cellular biochemistry.

Roscovitine Differentially Affects Asynchronously Growing and Synchronized Human MCF‐7 Breast Cancer Cells

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2009, Annals of the New York Academy of Sciences.

Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.

J. Węsierska‐Gądek, O. Komina, 2008, Biochemical pharmacology.

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

J. Węsierska‐Gądek, E. Walzi, O. Komina, 2009, Journal of cellular biochemistry.

R‐roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase‐dependent apoptosis

J. Węsierska‐Gądek, O. Komina, Z. Kiliańska, 2010, Journal of cellular biochemistry.

Characterization of Autoantibodies against Components of the Nuclear Pore Complexes

J. Węsierska‐Gądek, O. Komina, E. Penner, 2007, Annals of the New York Academy of Sciences.

Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen

J. Węsierska‐Gądek, O. Komina, J. Hanover, 2008, Journal of cellular biochemistry.

Natural Compounds as Specific Inhibitors of Cyclin-Dependent Kinases – Past, Present and Future

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2012 .

Whether to target single or multiple CDKs for therapy? That is the question

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2011, Journal of cellular physiology.

Interference with ER‐α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER‐positive breast cancer cells

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2011, Journal of cellular biochemistry.

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment

J. Węsierska‐Gądek, P. Smolewski, O. Komina, 2012, Medical Oncology.

Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2009, Acta biochimica Polonica.

Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway

C. Pirker, W. Berger, Z. Bago-Horvath, 2012, Neuroendocrinology.

Interference with Estrogen Receptor-α by Dietary Components: Impact on the Balance Between Cell Proliferation and Cell Death

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2012 .

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen‐induced phosphorylation of ER‐α in human ER‐positive breast cancer cells

J. Węsierska‐Gądek, O. Komina, M. Maurer, 2011, Journal of cellular biochemistry.

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells☆

J. Węsierska‐Gądek, O. Komina, A. Składanowski, 2012, Biochemical pharmacology.